What the business is, and whether it's a good one at a fair price.
Makes active pharmaceutical ingredients (APIs) and finished formulations, with a portfolio centred on immunosuppressants and related therapies. Exports are a major growth lever and the API segment is the faster-moving part of the mix. The formulation side is anchored by its Unit-II facility, which cleared inspections from Kenya's Pharmacy and Poisons Board and Uganda's National Drug Authority in June 2026, adding to an earlier ANVISA approval in Brazil. The USFDA approved ANDAs for Tofacitinib Tablets (5 mg and 10 mg, used in rheumatoid arthritis) and Mycophenolate Mofetil, opening US generic supply. Cellimmune Biotech became a wholly owned subsidiary from April 2026 and Stellon Biotech has started commercial operations, extending the manufacturing base. To control power costs, it is investing Rs 6.3 Cr in FSGE Renewable Power, a special purpose vehicle building a 6.3 MW wind and 6.3 MW solar hybrid plant at its Limbasi facility. The cost structure is dominated by materials at 24.1% of FY26 revenue, followed by other operating expenses at 25.1% and employee costs at 16.8%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from CONCORD BIOTECH LIMITED's filed financials and exchange disclosures
CONCORD BIOTECH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol CONCORDBIO.
Yes. Over the trailing twelve months CONCORD BIOTECH LIMITED reported a net profit of ₹273 Cr on revenue of ₹1,108 Cr.
Yes. The dividend yield is 0.71% at the current price. It paid out 43% of its profit as dividend in FY26.
Effectively yes. It holds ₹12 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, CONCORD BIOTECH LIMITED ranks 136 of 169 in Pharmaceuticals — cheaper than 20% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session CONCORD BIOTECH LIMITED moves 1.21% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by CONCORD BIOTECH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
